

A prospective, randomized study comparing outcomes  
intensity-modulated radiotherapy vs. conventional two  
treatment of nasopharyngeal carcinoma

Radiotherapy and Oncology

104, 286-293

DOI: [10.1016/j.radonc.2012.08.013](https://doi.org/10.1016/j.radonc.2012.08.013)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of maximum primary tumor diameter in nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2013, 13, 260.	1.1	17
2	Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1577-1583.	1.1	24
3	Single arc volumetric-modulated arc therapy is sufficient for nasopharyngeal carcinoma: a dosimetric comparison with dual arc VMAT and dynamic MLC and step-and-shoot intensity-modulated radiotherapy. <i>Radiation Oncology</i> , 2013, 8, 237.	1.2	28
4	Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. <i>Medical Oncology</i> , 2013, 30, 710.	1.2	19
5	Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 2462-2466.	2.9	27
6	High-Dose and Extended-Field Intensity Modulated Radiation Therapy for Early-Stage NK/T-Cell Lymphoma of Waldeyer's Ring: Dosimetric Analysis and Clinical Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1086-1093.	0.4	51
7	Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. <i>British Journal of Cancer</i> , 2013, 109, 2987-2997.	2.9	50
8	The Potential of Helical Tomotherapy in the Treatment of Head and Neck Cancer. <i>Oncologist</i> , 2013, 18, 697-706.	1.9	21
9	Does MRI-Detected Cranial Nerve Involvement Affect the Prognosis of Locally Advanced Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy?. <i>PLoS ONE</i> , 2014, 9, e100571.	1.1	10
10	Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2014, 9, e110765.	1.1	31
11	Value Considerations in the Treatment of Head and Neck Cancer: Radiation, Chemotherapy, and Supportive Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e296-e303.	1.8	9
12	3,3'-Diindolylmethane inhibits the invasion and metastasis of nasopharyngeal carcinoma cells in vitro and in vivo by regulation of epithelial mesenchymal transition. <i>Experimental and Therapeutic Medicine</i> , 2014, 7, 1635-1638.	0.8	12
13	Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Compared with Concurrent Chemoradiotherapy Alone for the Treatment of Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Controlled Study. <i>Current Oncology</i> , 2014, 21, 408-417.	0.9	18
14	Prognostic Value of Grading Masticator Space Involvement in Nasopharyngeal Carcinoma according to MR Imaging Findings. <i>Radiology</i> , 2014, 273, 136-143.	3.6	26
15	Cognitive function, mood, and sleep quality in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer: a prospective study. <i>Psycho-Oncology</i> , 2014, 23, 1185-1191.	1.0	35
16	Clinical Study of Nasopharyngeal Carcinoma Treated by Helical Tomotherapy in China: 5-Year Outcomes. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	12
17	Evolution of treatment for nasopharyngeal cancer - Success and setback in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , 2014, 110, 377-384.	0.3	300
18	Intensity-modulated radiation therapy for head and neck cancer: Systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2014, 110, 9-15.	0.3	224

#	ARTICLE	IF	CITATIONS
19	Salivary gland transfer to prevent radiation-induced xerostomia: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2014, 50, 77-83.	0.8	43
20	Clinical observation and quality of life in terms of nasal sinusitis after radiotherapy for nasopharyngeal carcinoma: long-term results from different nasal irrigation techniques. <i>British Journal of Radiology</i> , 2014, 87, 20140043.	1.0	15
22	Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 261-269.	0.4	51
25	Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: A long-term follow-up study. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2014, 43, 30.	0.9	14
26	Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study. <i>BMC Cancer</i> , 2014, 14, 136.	1.1	27
27	Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2014, 9, 56.	1.2	44
28	Primary Tumor Regression Speed After Radiation Therapy and Its Prognostic Significance in Nasopharyngeal Carcinoma: A Retrospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S521.	0.4	0
29	Primary tumor volume should be included in the TNM staging system of nasopharyngeal carcinoma. <i>Medical Hypotheses</i> , 2014, 82, 486-487.	0.8	12
30	Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 404-408.	0.3	24
31	Current controversies in radiotherapy for nasopharyngeal carcinoma (NPC). <i>Oral Oncology</i> , 2014, 50, 907-912.	0.8	16
33	Prognostic value of parotid lymph node metastasis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. <i>Scientific Reports</i> , 2015, 5, 13919.	1.6	10
34	éé,éf"ç™(Eã«ã³/4ãª™ã,«ä½/2žã³/4µè¥²æ€šæ²»ç™,ã©æ—°ã±•é—«â€•æ"³/4â°„çšæ²»ç™,â€. <i>Journal of Otolaryngology of Japan</i> , 2015, 118		
35	Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. <i>Radiology and Oncology</i> , 2015, 49, 155-162.	0.6	15
36	Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis. <i>Scientific Reports</i> , 2015, 5, 17378.	1.6	23
37	Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2015, 15, 810.	1.1	24
38	The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2015, 15, 977.	1.1	21
39	Different setup errors assessed by weekly cone-beam computed tomography on different registration in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. <i>OncoTargets and Therapy</i> , 2015, 8, 2545.	1.0	15
40	Elevated High-Sensitivity C-Reactive Protein Levels Predict Decreased Survival for Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era. <i>PLoS ONE</i> , 2015, 10, e0122965.	1.1	21

#	ARTICLE	IF	CITATIONS
41	The Impact of Reduced-Volume, Intensity-Modulated Radiation Therapy on Disease Control in Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0125283.	1.1	7
42	Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0141332.	1.1	36
43	Prognostic Value of Classifying Parapharyngeal Extension in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging. BioMed Research International, 2015, 2015, 1-8.	0.9	3
44	Replanning Criteria and Timing Definition for Parotid Protection-Based Adaptive Radiation Therapy in Nasopharyngeal Carcinoma. BioMed Research International, 2015, 2015, 1-8.	0.9	19
45	Quality of Life of Nasopharyngeal Cancer Survivors in China. Current Oncology, 2015, 22, 142-147.	0.9	29
46	Analysis of the efficacy of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma with involvement of the cervical spine. Oncology Letters, 2015, 10, 2731-2738.	0.8	7
47	A dosimetric comparison of two-phase adaptive intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer. Journal of Radiation Research, 2015, 56, 529-538.	0.8	20
48	Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies. Hematology/Oncology Clinics of North America, 2015, 29, 1107-1122.	0.9	39
49	Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma: Validation of the 7th edition AJCC staging system. Oral Oncology, 2015, 51, 254-259.	0.8	75
50	Intensity modulated radiation therapy in nasopharyngeal carcinoma. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2015, 132, 147-151.	0.4	23
51	Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncology, 2015, 51, 950-956.	0.8	19
52	Nouvelles techniques de radiothérapie des tumeurs de la face et du cou : État des lieux et perspectives. Oncologie, 2015, 17, 225-231.	0.2	0
53	Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis. Medical Oncology, 2015, 32, 224.	1.2	27
54	Definitive radiotherapy for head and neck squamous cell carcinoma: update and perspectives on the basis of EBM. Japanese Journal of Clinical Oncology, 2015, 45, 235-243.	0.6	8
55	Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?. BMC Cancer, 2015, 15, 305.	1.1	9
56	Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 91, 952-960.	0.4	197
57	Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. European Journal of Cancer, 2015, 51, 2587-2595.	1.3	245
58	Expanding global access to radiotherapy. Lancet Oncology, The, 2015, 16, 1153-1186.	5.1	709

#	ARTICLE	IF	CITATIONS
59	Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires. Expert Review of Anticancer Therapy, 2015, 15, 109-119.	1.1	21
60	Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer, 2015, 15, 429.	1.1	13
61	Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncology, 2015, 51, 1041-1046.	0.8	172
63	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. Journal of Clinical Oncology, 2015, 33, 3356-3364.	0.8	579
64	Irradiation conformationnelle avec modulation d'intensité des cancers du rhinopharynx. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2015, 132, 142-146.	0.0	0
65	Treatment results of pediatric nasopharyngeal carcinoma, NCI, Cairo University experience. Journal of the Egyptian National Cancer Institute, 2015, 27, 119-128.	0.6	11
66	Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience. Oncologist, 2015, 20, 279-290.	1.9	3
67	Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: An analysis of survival and treatment toxicities. Oral Oncology, 2015, 51, 190-194.	0.8	29
68	Dry Mouth. , 2015, , .		5
69	Prognostic Evaluation of Nasopharyngeal Carcinoma with Bone-Only Metastasis after Therapy. Yonsei Medical Journal, 2016, 57, 840.	0.9	18
70	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA >=4000 copies/ml: a matched study. Oncotarget, 2016, 7, 29739-29748.	0.8	15
71	Excellent Survival Regardless of Disease Stage in Patients with Advanced Nasopharyngeal Cancer. Tumori, 2016, 102, 381-386.	0.6	4
72	Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget, 2016, 7, 33408-33417.	0.8	20
73	Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway. Biochemistry Research International, 2016, 2016, 1-10.	1.5	12
74	Prognostic Value of Cavernous Sinus Invasion in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy. PLoS ONE, 2016, 11, e0146787.	1.1	6
75	Comparison of long-term survival and toxicity of simultaneous integrated boost vs conventional fractionation with intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma. OncoTargets and Therapy, 2016, 9, 1865.	1.0	11
76	How to minimize morbidity in radiotherapy of pharyngolaryngeal tumors?. Current Opinion in Otolaryngology and Head and Neck Surgery, 2016, 24, 163-169.	0.8	5
77	Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. Head and Neck, 2016, 38, E1102-9.	0.9	39

#	ARTICLE	IF	CITATIONS
78	Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience. <i>Laryngoscope</i> , 2016, 126, 620-626.	1.1	16
79	Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1061-7.	0.9	46
80	Evolution of postirradiated sudden deafness in nasopharyngeal carcinoma survivors during the past two decades. <i>Laryngoscope</i> , 2016, 126, 2016-2021.	1.1	5
81	Trismus, xerostomia and nutrition status in nasopharyngeal carcinoma survivors treated with radiation. <i>European Journal of Cancer Care</i> , 2016, 25, 440-448.	0.7	23
82	Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. <i>Head and Neck</i> , 2016, 38, E1026-32.	0.9	72
83	Does primary tumor volume predict the outcome of pediatric nasopharyngeal carcinoma?: A prospective single-arm study using neoadjuvant chemotherapy and concomitant chemotherapy with intensity modulated radiotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 143-150.	0.7	11
84	Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment. <i>Chinese Journal of Cancer</i> , 2016, 35, 98.	4.9	32
85	Surgical techniques in radiation induced temporal lobe necrosis in nasopharyngeal carcinoma patients. <i>Neurologia I Neurochirurgia Polska</i> , 2016, 50, 172-179.	0.6	5
86	A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 727-734.	0.6	25
87	Impact of X-linked inhibitor of apoptosis protein on survival of nasopharyngeal carcinoma patients following radiotherapy. <i>Tumor Biology</i> , 2016, 37, 11825-11833.	0.8	8
88	Forty-six cases of nasopharyngeal carcinoma treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center. <i>Chinese Journal of Cancer</i> , 2016, 35, 37.	4.9	6
89	IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 377-385.	1.0	42
90	Cancer of the Nasopharynx. , 2016, , 51-63.		0
91	Assessing head and neck cancer patient preferences and expectations: A systematic review. <i>Oral Oncology</i> , 2016, 62, 44-53.	0.8	39
92	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 203-239.	157.7	419
94	Intensity-modulated radiotherapy controls nasopharyngeal carcinoma distant metastasis and improves survival of patients. <i>SpringerPlus</i> , 2016, 5, 1459.	1.2	9
95	High-risk factors of parotid lymph node metastasis in nasopharyngeal carcinoma: a case-control study. <i>Radiation Oncology</i> , 2016, 11, 113.	1.2	15
96	Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population. <i>Medicine (United States)</i> , 2016, 95, e4494.	0.4	24

#	ARTICLE	IF	CITATIONS
97	Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. <i>Head and Neck</i> , 2016, 38, E1886-95.	0.9	102
98	Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. <i>Chinese Journal of Cancer</i> , 2016, 35, 2.	4.9	62
99	Intensity-modulated radiotherapy for localized nasopharyngeal amyloidosis. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 944-950.	1.0	14
100	Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 379-386.	0.4	6
101	Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. <i>Head and Neck</i> , 2016, 38, E1481-7.	0.9	78
102	Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature. <i>Head and Neck</i> , 2016, 38, E2130-42.	0.9	45
103	Radiation caries in nasopharyngeal carcinoma patients after intensity-modulated radiation therapy: A cross-sectional study. <i>Journal of Dental Sciences</i> , 2016, 11, 1-7.	1.2	8
104	Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia. <i>Journal of Radiation Research</i> , 2016, 57, 44-49.	0.8	6
105	The management of head and neck tumors with high technology radiation therapy. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 99-110.	1.1	19
106	Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. <i>Medicine (United States)</i> , 2016, 95, e2642.	0.4	29
107	Elective Nodal Irradiation and Patterns of Failure in Head and Neck Cancer After Primary Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 775-782.	0.4	30
108	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 53, 67-73.	0.8	44
109	Nasopharyngeal carcinoma. <i>Lancet</i> , The, 2016, 387, 1012-1024.	6.3	1,045
110	Nasopharyngeal carcinoma with intracranial extension in the era of intensity-modulated radiotherapy: case-control study using propensity score matching method. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2209-2215.	0.8	3
111	Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv291.	3.0	281
112	2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF- $\kappa$ B/HIF-1 signaling pathway inactivation and EMT reversal. <i>Oncology Reports</i> , 2017, 37, 793-802.	1.2	45
115	The outcome of the first 100 nasopharyngeal cancer patients in thailand treated by helical tomotherapy. <i>Radiology and Oncology</i> , 2017, 51, 351-356.	0.6	1
116	Clinical Evaluation and Management of Radiation Fibrosis Syndrome. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2017, 28, 89-100.	0.7	41

#	ARTICLE	IF	CITATIONS
117	AHNS Series "Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. <i>Head and Neck</i> , 2017, 39, 201-205.	0.9	13
118	The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 868-883.	0.4	45
119	Parotid gland mean dose as a xerostomia predictor in low-dose domains. <i>Acta Oncologica</i> , 2017, 56, 1197-1203.	0.8	25
120	Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study. <i>Radiotherapy and Oncology</i> , 2017, 123, 394-400.	0.3	25
121	A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1563-1572.	1.2	50
122	The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States. <i>Cancer</i> , 2017, 123, 3176-3185.	2.0	51
123	Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center. <i>Oral Oncology</i> , 2017, 69, 26-32.	0.8	75
125	The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1263-1273.	1.2	62
126	Critical Issues in Head and Neck Oncology. , 2017, , .		0
127	Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1691-1700.	0.8	10
128	Neuromuscular complications of radiation therapy. <i>Muscle and Nerve</i> , 2017, 56, 1031-1040.	1.0	31
129	Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2017, 73, 97-104.	0.8	13
131	Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy. <i>Clinical Nuclear Medicine</i> , 2017, 42, 655-662.	0.7	15
132	S100A6 promotes cell proliferation in human nasopharyngeal carcinoma via the p38/MAPK signaling pathway. <i>Molecular Carcinogenesis</i> , 2017, 56, 972-984.	1.3	29
133	Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis. <i>Clinical and Translational Oncology</i> , 2017, 19, 470-476.	1.2	25
134	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 377-382.	1.1	16
135	Incidence of small lymph node metastases in patients with nasopharyngeal carcinoma: Clinical implications for prognosis and treatment. <i>Head and Neck</i> , 2017, 39, 305-310.	0.9	7
136	Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. <i>Journal of Cancer</i> , 2017, 8, 3718-3724.	1.2	25



#	ARTICLE	IF	CITATIONS
137	Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3329-3336.	1.0	17
138	Long-term Patterns of Regional Failure for Nasopharyngeal Carcinoma following Intensity-Modulated Radiation Therapy. <i>Journal of Cancer</i> , 2017, 8, 993-999.	1.2	18
139	Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?. <i>Cancers</i> , 2017, 9, 135.	1.7	49
140	R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. <i>Frontiers in Oncology</i> , 2017, 7, 59.	1.3	90
141	Chemotherapy use and survival in stage II nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 102573-102580.	0.8	11
142	Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3853-3860.	1.0	31
143	The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5677-5683.	1.0	13
144	Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?. <i>Journal of Cancer</i> , 2017, 8, 976-982.	1.2	29
145	Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2017, 36, 98.	4.9	29
146	Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2017, 17, 506.	1.1	20
147	Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2017, 17, 788.	1.1	0
148	Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. <i>Radiation Oncology</i> , 2017, 12, 184.	1.2	21
149	Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 41166-41177.	0.8	68
150	Diagnostic, Therapeutic and Evolutionary Characteristics of Nasopharyngeal Cancer in Morocco. <i>Journal of Cancer Science &amp; Therapy</i> , 2017, 09, .	1.7	2
151	Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 78096-78104.	0.8	14
152	Higher N stage and serum ferritin, but lower serum albumin levels are associated with distant metastasis and poor survival in patients with nasopharyngeal carcinoma following intensity-modulated radiotherapy. <i>Oncotarget</i> , 2017, 8, 73177-73186.	0.8	11
153	An evaluation of nutrition intervention during radiation therapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 83723-83733.	0.8	30
154	Partial Laryngeal IMRT for T2N0 Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 941-949.	0.4	17

#	ARTICLE	IF	CITATIONS
155	Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 1003-1014.	2.5	35
156	Survivorship Care Planning and Quality of Life. <i>Cancer Treatment and Research</i> , 2018, 174, 271-282.	0.2	5
157	Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study. <i>Radiotherapy and Oncology</i> , 2018, 129, 23-29.	0.3	29
158	Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: Based on hazard-rate and patterns of recurrence. <i>Oral Oncology</i> , 2018, 76, 61-67.	0.8	11
159	A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 375-385.	1.0	30
160	Impact of minimum point dose on local control and toxicity in T3-4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 265-271.	0.6	7
161	Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 80, 1-8.	0.8	20
162	Proton Therapy for Head and Neck Cancers. <i>Seminars in Radiation Oncology</i> , 2018, 28, 53-63.	1.0	89
163	Comparison of intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and a 3-dimensional conformal parotid gland-sparing radiotherapy (ConPas 3D-CRT) in treatment of nasopharyngeal carcinoma: a mono-institutional experience. <i>Radiologia Medica</i> , 2018, 123, 217-226.	4.7	7
164	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.3	214
165	Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma. <i>Head and Neck</i> , 2018, 40, 590-595.	0.9	11
166	Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 891-899.	0.8	81
167	Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 641-649.	0.6	2
168	MicroRNA-153 affects nasopharyngeal cancer cell viability by targeting TGF- $\beta$ 2. <i>Oncology Letters</i> , 2018, 17, 646-651.	0.8	11
169	Nasopharyngeal cancer: towards the ever elusive goal of standardization. <i>Annals of Nasopharynx Cancer</i> , 0, 1, 1-1.	0.5	0
170	Local regression and control of T1-2 nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer Medicine</i> , 2018, 7, 6010-6019.	1.3	8
171	Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma. <i>Oncotarget</i> , 2018, 9, 9992-10004.	0.8	25
172	RGS17 inhibits tumorigenesis and improves 5-fluorouracil sensitivity in nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7591-7600.	1.0	5

#	ARTICLE	IF	CITATIONS
173	Can We Expect Less Toxicities with Newer Forms of Radiotherapy?. , 2018, , 181-212.		0
175	Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. BMC Cancer, 2018, 18, 1279.	1.1	13
176	Which nasopharyngeal cancer patients need adaptive radiotherapy?. BMC Cancer, 2018, 18, 1234.	1.1	12
177	Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography. OncoTargets and Therapy, 2018, Volume 11, 7909-7917.	1.0	4
178	Patterns of failure, treatment outcomes and late toxicities of head and neck cancer in the current era of IMRT. Oral Oncology, 2018, 86, 225-233.	0.8	21
179	Pattern of geometric changes of parotid gland in conventional and intensity-modulated radiotherapy in nasopharyngeal cancer patients. Journal of Radiotherapy in Practice, 2018, 17, 274-278.	0.2	1
180	Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. Journal of Cancer, 2018, 9, 3447-3455.	1.2	11
181	Prognostic value of tumor burden in nasopharyngeal carcinoma. Cancer Management and Research, 2018, Volume 10, 3169-3175.	0.9	14
182	Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. Journal of Cancer, 2018, 9, 3023-3031.	1.2	10
183	Pathologic study of tumour extension for clinically localized unilateral nasopharyngeal carcinoma: Should the contralateral side be included in the clinical target volume?. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 540-547.	0.9	4
184	Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. Journal of Radiation Research, 2018, 59, 446-455.	0.8	26
185	A novel N staging system for NPC based on IMRT and RTOG guidelines for lymph node levels: Results of a prospective multicentric clinical study. Oncology Letters, 2018, 16, 308-316.	0.8	5
186	Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis. Cancer Management and Research, 2018, Volume 10, 1419-1428.	0.9	29
187	Patterns of Failure and Survival Trends Of 720 Patients with Stage I Nasopharyngeal Carcinoma Diagnosed from 1990-2012: A Large-scale Retrospective Cohort Study. Journal of Cancer, 2018, 9, 1308-1317.	1.2	11
188	Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. PLoS ONE, 2018, 13, e0200137.	1.1	64
189	The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC Cancer, 2018, 18, 740.	1.1	31
190	Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis. Revista Da AssociaÃo MÃ©dica Brasileira, 2018, 64, 318-323.	0.3	6
191	Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Radiation Oncology, 2018, 13, 148.	1.2	23

#	ARTICLE	IF	CITATIONS
192	Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Biology and Therapy</i> , 2018, 19, 1102-1107.	1.5	18
193	Unilateral cochlea sparing in locoregionally advanced head and neck cancer: aÂplanning study. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 1124-1131.	1.0	3
194	Risk, pattern and survival impact of second primary tumors in patients with nasopharyngeal carcinoma following definitive intensityâ€modulated radiotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 48-55.	0.7	15
195	10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2019, 24, e38-e45.	1.9	57
196	Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma. <i>Brazilian Journal of Otorhinolaryngology</i> , 2019, 85, 705-715.	0.4	6
197	Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy. <i>Journal of Cancer</i> , 2019, 10, 3899-3907.	1.2	5
198	Three-dimensional conformal radiotherapy versus intensity modulated radiotherapy with simultaneous integrated boost in the treatment of locally advanced head and neck carcinoma. <i>Neoplasma</i> , 2019, 66, 830-838.	0.7	6
199	The Association Between the Development of Radiation Therapy, Image Technology, and Chemotherapy, and the Survival of Patients With Nasopharyngeal Carcinoma: A Cohort Study From 1990 to 2012. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 581-590.	0.4	80
200	Update in pediatric nasopharyngeal undifferentiated carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20190107.	1.0	17
201	Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study. <i>Radiology: Artificial Intelligence</i> , 2019, 1, e180075.	3.0	32
202	The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0219611.	1.1	57
203	Future of Radiotherapy in Nasopharyngeal Carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20190209.	1.0	71
204	Pre-treatment Serum Lactate Dehydrogenase Predicts Distant Metastasis and Poor Survival in Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3657-3664.	1.2	19
205	&lt;p&gt;Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 6365-6376.	0.9	26
206	Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRTâ€A study by the HKNPCSG. <i>Head and Neck</i> , 2019, 41, 3661-3669.	0.9	28
207	Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and doseâ€toxicity relationship. <i>Radiotherapy and Oncology</i> , 2019, 138, 93-98.	0.3	25
208	Clinical outcome and toxicity after simultaneous integrated boost IMRT in head and neck squamous cell cancer patients. <i>Oral Oncology</i> , 2019, 98, 132-140.	0.8	18
209	Technological evolution of radiation treatment: Implications for clinical applications. <i>Seminars in Oncology</i> , 2019, 46, 193-201.	0.8	29

#	ARTICLE	IF	CITATIONS
210	Dynamical Diffraction Calculations of Incommensurate Modulations in Crystals. <i>Microscopy and Microanalysis</i> , 2019, 25, 1928-1929.	0.2	2
211	Experimental and Numerical Study on Impact Behavior of Welded Hollow Sphere Joint under Continuous Impact Load. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 304, 042029.	0.2	0
212	Reverberation suppression using non-negative matrix factorization to detect low-Doppler target with continuous wave active sonar. <i>Eurasip Journal on Advances in Signal Processing</i> , 2019, 2019, .	1.0	10
213	Paranasal sinus invasion suggested T4 classification of patients of nasopharyngeal carcinoma: A two-center retrospective investigation. <i>Head and Neck</i> , 2019, 41, 4088-4097.	0.9	3
214	Assessment of Nasopharyngeal Cancer in Young Patients Aged ≤ 30 Years. <i>Frontiers in Oncology</i> , 2019, 9, 1179.	1.3	16
215	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 567-580.	0.4	96
216	Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort. <i>Cancer Medicine</i> , 2019, 8, 4214-4225.	1.3	17
217	Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study. <i>BMC Cancer</i> , 2019, 19, 554.	1.1	11
219	Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20190068.	1.0	10
220	Nasopharyngeal carcinoma. <i>Lancet, The</i> , 2019, 394, 64-80.	6.3	1,667
221	The changing therapeutic landscape of head and neck cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 669-683.	12.5	454
222	Effect of Early Nutrition Intervention on Advanced Nasopharyngeal Carcinoma Patients Receiving Chemoradiotherapy. <i>Journal of Cancer</i> , 2019, 10, 3650-3656.	1.2	36
223	Standard of Care for Nasopharyngeal Carcinoma (2018–2020). , 2019, , 205-238.		1
224	International Consensus on Delineation of Target Volumes and Organs at Risk. , 2019, , 239-261.		2
225	Advances in Radiotherapy. , 2019, , 263-288.		2
226	Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control. <i>Cancers</i> , 2019, 11, 379.	1.7	15
227	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. <i>Radiology</i> , 2019, 291, 677-686.	3.6	221
228	Ginsenoside Rg3 Inhibits Migration and Invasion of Nasopharyngeal Carcinoma Cells and Suppresses Epithelial Mesenchymal Transition. <i>BioMed Research International</i> , 2019, 2019, 1-11.	0.9	13

#	ARTICLE	IF	CITATIONS
229	Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 504-516.	1.0	20
230	Concluding Chapter. , 2019, , 359-368.		1
231	Development and validation of a model for temporal lobe necrosis for nasopharyngeal carcinoma patients with intensity modulated radiation therapy. <i>Radiation Oncology</i> , 2019, 14, 42.	1.2	19
232	The prevalence and impact of cervical spine pathologies in patients with nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2019, 90, 48-53.	0.8	4
233	Adverse Cochlear Effects After Head and Neck Cancer Therapy. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2019, 71, 740-747.	0.3	1
234	Results of a combination treatment with intensity modulated radiotherapy and active raster-scanning carbon ion boost for adenoid cystic carcinoma of the minor salivary glands of the nasopharynx. <i>Oral Oncology</i> , 2019, 91, 39-46.	0.8	25
235	22 Carcinoma of the Nasopharynx. , 2019, , .		0
236	Safety and Effectiveness of De-escalated Radiation Dose in T1-3 Nasopharyngeal Carcinoma: A Propensity Matched Analysis. <i>Journal of Cancer</i> , 2019, 10, 5057-5064.	1.2	8
237	Platelet-to-lymphocyte ratio as a potential prognostic factor in nasopharyngeal carcinoma. <i>Medicine (United States)</i> , 2019, 98, e17176.	0.4	7
238	Clinically applicable deep learning framework for organs at risk delineation in CT images. <i>Nature Machine Intelligence</i> , 2019, 1, 480-491.	8.3	100
239	Predictors for improvement of xerostomia in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. <i>Medicine (United States)</i> , 2019, 98, e17030.	0.4	12
240	Oncologic outcomes of IMRT versus CRT for nasopharyngeal carcinoma. <i>Medicine (United States)</i> , 2019, 98, e15951.	0.4	22
241	The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. <i>International Journal of Cancer</i> , 2019, 144, 1713-1722.	2.3	82
242	Cancers of the Head and Neck. , 2019, , 103-114.		0
243	Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma: toxicity/quality of life and survival. <i>Head and Neck</i> , 2019, 41, 1282-1289.	0.9	6
244	Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 45-51.	0.4	13
245	Bone Subtraction Iodine Imaging Using Area Detector CT for Evaluation of Skull Base Invasion by Nasopharyngeal Carcinoma. <i>American Journal of Neuroradiology</i> , 2019, 40, 135-141.	1.2	13
246	The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 131, 35-44.	0.3	28

#	ARTICLE	IF	CITATIONS
247	Cochlea sparing with a stratified scheme of dose limitation employed in intensity-modulated radiotherapy for nasopharyngeal carcinoma: A dosimetry study. <i>Medical Dosimetry</i> , 2019, 44, 226-232.	0.4	6
248	Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes. <i>Clinical and Translational Oncology</i> , 2019, 21, 781-789.	1.2	5
249	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. <i>Journal of the National Cancer Institute</i> , 2020, 112, 229-237.	3.0	15
250	Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 429-439.	1.2	6
251	The relations of dosimetric parameters with long-term outcomes and late toxicities in advanced Tâ€stage nasopharyngeal carcinoma with IMRT. <i>Head and Neck</i> , 2020, 42, 85-92.	0.9	9
252	Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. <i>European Radiology</i> , 2020, 30, 816-822.	2.3	23
253	Survival ofÂstage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study. <i>Cancer Medicine</i> , 2020, 9, 1287-1297.	1.3	12
254	Malignant Soft-Tissue Sarcomas. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 161-175.	0.9	18
255	Dosimetric impact on changes in target volumes during intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 41-45.	0.3	16
256	Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients. <i>Journal of Radiation Research</i> , 2020, 61, 161-168.	0.8	5
257	The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2020, 101, 104520.	0.8	16
258	Cancer Rehabilitation. <i>Medical Clinics of North America</i> , 2020, 104, 239-250.	1.1	18
259	A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Â± Chemotherapy. <i>Clinical Oncology</i> , 2020, 32, 238-249.	0.6	11
260	Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65Âyears). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 270-279.	1.0	11
261	Comparison of Long-Term Outcomes and Sequelae Between Children and Adult Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 848-856.	0.4	21
262	Hypothyroidism after radiotherapy for nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 4, 3-3.	0.5	4
264	Cancro dellâ€™orofaringe. <i>EMC - Otorinolaringoiatria</i> , 2020, 19, 1-17.	0.0	0
266	Chemoradiotherapy combined with NK cell transfer in a patient with recurrent and metastatic nasopharyngeal carcinoma inducing long-term tumor control. <i>Medicine (United States)</i> , 2020, 99, e22785.	0.4	2

#	ARTICLE	IF	CITATIONS
267	Preradiation tooth extraction and jaw osteoradionecrosis: Nationwide population-based retrospective study in Taiwan. <i>Clinical Otolaryngology</i> , 2020, 45, 896-903.	0.6	5
268	Emerging radiotherapy technologies and trends in nasopharyngeal cancer. <i>Cancer Communications</i> , 2020, 40, 395-405.	3.7	18
269	Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. <i>Medicine (United States)</i> , 2020, 99, e21325.	0.4	7
270	A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma—To Know, Then to Measure. <i>Frontiers in Oncology</i> , 2020, 10, 1076.	1.3	1
271	Brachytherapy in India: Learning from the past and looking into the future. <i>Brachytherapy</i> , 2020, 19, 861-873.	0.2	3
272	Toxicity and dosimetric analysis of nasopharyngeal carcinoma patients undergoing radiotherapy with IMRT or VMAT: A regional center's experience. <i>Oral Oncology</i> , 2020, 109, 104978.	0.8	10
273	Prognosis of Extracapsular Spread of Cervical Lymph Node Metastases in Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 523956.	1.3	10
274	Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1417.	1.3	11
275	Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implications for cancer control program in India. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 492-499.	0.2	9
276	Assessment of Hearing Loss in Patients Receiving Chemoradiotherapy in Adjuvant Setting for Head and Neck Malignancy. <i>Annals of Otolaryngology and Neurology</i> , 2020, 3, 16-22.	0.1	0
277	<p></p>Outcomes and Experiences of Child-Bearing Women with Nasopharyngeal Carcinoma</p><p></p>Cancer Management and Research, 2020, Volume 12, 8047-8054.	0.9	0
278	Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. <i>Radiation Oncology</i> , 2020, 15, 218.	1.2	38
279	<p></p>Surgical Treatment Outcomes of Spinal Metastases of Nasopharyngeal Carcinoma: The First Report of 30 Patients from a Single Center</p><p></p>Cancer Management and Research, 2020, Volume 12, 6999-7008.	0.9	5
280	Combination of precision radiotherapy with chemotherapy and immunotherapy in non-recurrent/metastatic nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 4, 5-5.	0.5	2
282	Nutritional Status and Its Association With Radiation-Induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma During Radiotherapy: A Prospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 594687.	1.3	16
284	Is nasopharyngeal carcinoma in young patients a distinct clinical entity? A single-institution case matched analysis in the era of intensity-modulated radiotherapy. <i>Oral Oncology</i> , 2020, 107, 104779.	0.8	1
285	TSPAN8 and distant metastasis of nasopharyngeal carcinoma cells. <i>Annals of Translational Medicine</i> , 2020, 8, 165-165.	0.7	3
286	Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors. <i>Frontiers in Oncology</i> , 2020, 10, 930.	1.3	31



#	ARTICLE	IF	CITATIONS
287	New developments in nasopharyngeal cancer. , 2020, , 277-299.		0
288	Radiation therapy and chemotherapy in early and advanced nasopharyngeal cancer. , 2020, , 189-227.		0
289	Development of a self-constrained 3D DenseNet model in automatic detection and segmentation of nasopharyngeal carcinoma using magnetic resonance images. Oral Oncology, 2020, 110, 104862.	0.8	49
290	Dosimetric comparison between RapidArc and HyperArc techniques in salvage stereotactic body radiation therapy for recurrent nasopharyngeal carcinoma. Radiation Oncology, 2020, 15, 164.	1.2	15
291	Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis. Radiation Oncology, 2020, 15, 160.	1.2	4
292	Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level. BMC Cancer, 2020, 20, 89.	1.1	8
293	Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy. Acta Oncologica, 2020, 59, 541-548.	0.8	17
294	Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2020, 107, 172-180.	0.4	6
295	Current management of stage IV nasopharyngeal carcinoma without distant metastasis. Cancer Treatment Reviews, 2020, 85, 101995.	3.4	28
297	Predictive quantitative ultrasound radiomic markers associated with treatment response in head and neck cancer. Future Science OA, 2020, 6, FSO433.	0.9	18
298	Clinical Evaluation and Management of Cancer Survivors with Radiation Fibrosis Syndrome. Seminars in Oncology Nursing, 2020, 36, 150982.	0.7	10
299	A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015). International Journal of Clinical Oncology, 2020, 25, 1250-1259.	1.0	15
300	A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 672-682.	0.4	22
301	Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemoradiotherapy in the modern era. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2020, 6, 25-33.	0.7	2
302	Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 282.	1.3	8
303	Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy. Radiation Oncology, 2020, 15, 84.	1.2	12
304	<p>Comparison of Radiation-Induced Secondary Malignancy Risk Between Sequential and Simultaneous Integrated Boost for the Treatment of Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy versus Volumetric-Modulated Arc Therapy</p>. Cancer Management and Research, 2020, Volume 12, 2513-2521.	0.9	3
305	Validation of Stage <sc>N3</sc> of the Eighth Edition <sc>AJCC</sc> Staging System for Nasopharyngeal Carcinoma. Laryngoscope, 2021, 131, 535-540.	1.1	2

#	ARTICLE	IF	CITATIONS
306	Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 188-197.	1.0	10
307	Health-Related Quality of Life Outcomes in Head and Neck Cancer: Results From a Prospective, Real-World Data Study With Brazilian Patients Treated With Intensity Modulated Radiation Therapy, Conformal and Conventional Radiation Techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 485-494.	0.4	4
308	Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 495-504.	0.4	3
309	Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03. <i>Radiotherapy and Oncology</i> , 2021, 154, 179-186.	0.3	24
310	Short-term and long-term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 456-466.	0.9	1
311	The prognostic role of prognostic nutritional index in nasopharyngeal carcinoma: A systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 66-77.	1.0	16
312	Investigation of the feasibility of synthetic MRI in the differential diagnosis of non-keratinising nasopharyngeal carcinoma and benign hyperplasia using different contoured methods for delineation of the region of interest. <i>Clinical Radiology</i> , 2021, 76, 238.e9-238.e15.	0.5	13
313	Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. <i>MedComm</i> , 2021, 2, 175-206.	3.1	24
314	Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110119.	0.8	5
315	Tumor subsites and risk of osteoradionecrosis of the jaw in patients with oral cavity cancer: a national-based cohort study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3425-3433.	0.8	11
316	Moderately Hypofractionated Intensity-modulated Radiotherapy With a Simultaneous Integrated Boost for Locally Advanced Head and Neck Cancer – Do Modern Techniques Fulfil Their Promise?. <i>In Vivo</i> , 2021, 35, 2801-2808.	0.6	5
317	A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3333-3344.	0.8	1
318	New Developments in the Management of Nasopharyngeal Carcinoma. , 2021, , 327-335.		0
319	Temporal Lobe Necrosis Following Radiotherapy in Nasopharyngeal Carcinoma: New Insight Into the Management. <i>Frontiers in Oncology</i> , 2020, 10, 593487.	1.3	8
320	Dosimetric Comparison of Helical Tomotherapy, Volumetric-Modulated Arc Therapy, and Intensity-Modulated Proton Therapy for Angiosarcoma of the Scalp. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382098586.	0.8	6
321	Intensity-Modulated Radiation Therapy for Nasopharyngeal Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 71-81.	0.0	0
322	Loosening Neuro-Optic Structures Dosimetric Constraints Provides High 5-Year Local Recurrence-Free Survival With Acceptable Toxicity in T4 Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 598320.	1.3	1
323	Effect of chemotherapy on survival in patients with stage T3-4N0M0 nasopharyngeal carcinoma. <i>Clinical Otolaryngology</i> , 2021, 46, 802-808.	0.6	1

#	ARTICLE	IF	CITATIONS
324	The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort. <i>Translational Oncology</i> , 2021, 14, 100990.	1.7	4
325	Durability of the parotid-sparing effect of intensity-modulated radiotherapy (<scp>IMRT</scp>) in early stage nasopharyngeal carcinoma: A 15-year follow-up of a randomized prospective study of <scp>IMRT</scp> versus two-dimensional radiotherapy. <i>Head and Neck</i> , 2021, 43, 1711-1720.	0.9	10
326	The evolution of bone marrow signal changes at the skull base in nasopharyngeal carcinoma patients treated with radiation therapy. <i>Radiologia Medica</i> , 2021, 126, 818-826.	4.7	4
327	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	0.8	178
328	Editorial: Advances in the Pathogenesis and Therapeutic Strategies for Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 647809.	1.3	5
329	Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies. <i>Anticancer Research</i> , 2021, 41, 1587-1592.	0.5	2
330	Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Journal of Radiation Research</i> , 2021, 62, 438-447.	0.8	12
331	Nongaussian Intravoxel Incoherent Motion Diffusion Weighted and Fast Exchange Regime Dynamic Contrast-Enhanced-MRI of Nasopharyngeal Carcinoma: Preliminary Study for Predicting Locoregional Failure. <i>Cancers</i> , 2021, 13, 1128.	1.7	4
332	Treatment Deescalation Strategies for Nasopharyngeal Cancer. <i>JAMA Oncology</i> , 2021, 7, 445.	3.4	18
333	Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era. <i>BMC Cancer</i> , 2021, 21, 327.	1.1	8
334	Multimodal Treatment With Orbital Organ Preservation in Adult Patients With Locally Advanced Small-Round-Cell Malignancy of the Nasal Cavity and Paranasal Sinus. <i>Frontiers in Oncology</i> , 2021, 11, 650385.	1.3	1
335	Geriatric nutritional risk index as an independent prognostic factor in locally advanced nasopharyngeal carcinoma treated using radical concurrent chemoradiotherapy: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2021, 9, 532-532.	0.7	8
336	Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2021, 16, 64.	1.2	5
337	Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29018.	0.8	11
338	Diffusion weighted imaging in submandibular gland sparing helical tomotherapy for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 157, 247-254.	0.3	5
339	Intensity-Modulated Proton Therapy for Nasopharynx Cancer: 2-year Outcomes from a Single Institution. <i>International Journal of Particle Therapy</i> , 2021, 8, 28-40.	0.9	8
340	Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance. <i>Cancer Medicine</i> , 2021, 10, 3613-3621.	1.3	10
341	Retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma. <i>PLoS ONE</i> , 2021, 16, e0253424.	1.1	2

#	ARTICLE	IF	CITATIONS
342	Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up. <i>Cancer Research and Treatment</i> , 2022, 54, 118-129.	1.3	10
343	Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2021, 16, 118.	1.2	2
344	IMRT improves local control in patients with nasopharyngeal carcinoma compared with conventional radiotherapy: propensity score-matched analysis. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1444-1451.	0.6	4
345	Intensity Modulated Proton Beam Therapy versus Volumetric Modulated Arc Therapy for Patients with Nasopharyngeal Cancer: A Propensity Score-Matched Study. <i>Cancers</i> , 2021, 13, 3555.	1.7	15
346	Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	23
347	Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 653050.	1.3	7
348	Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area. <i>Cancer Research and Treatment</i> , 2021, 53, 657-670.	1.3	12
349	External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. <i>Cancers</i> , 2021, 13, 4286.	1.7	4
350	Clinical Profile and Treatment Outcomes in Patients Treated with Intensity-Modulated Radiotherapy (IMRT) for Carcinoma Nasopharynx: A Retrospective Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-6.	0.6	1
351	Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: Clinical efficacy and late toxicity. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, , .	0.6	0
352	Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era. <i>Cancer Management and Research</i> , 2021, Volume 13, 6799-6810.	0.9	12
353	Proton Therapy in Head and Neck Cancer Treatment: State of the Problem and Development Prospects (Review). <i>Sovremennye Tehnologii V Medicine</i> , 2021, 13, 70.	0.4	7
354	Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study. <i>BMJ Open</i> , 2021, 11, e045417.	0.8	11
355	Progression-Free Survival Prediction in Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: Machine Learning vs. Traditional Statistics. <i>Journal of Personalized Medicine</i> , 2021, 11, 787.	1.1	7
356	Diagnosis and Therapy of Nasopharyngeal Carcinoma. , 0, , .		0
357	A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. <i>Radiation Oncology</i> , 2021, 16, 186.	1.2	4
358	Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 2825-2843.	0.8	45
359	Chemotherapy in Nasopharyngeal Carcinoma. , 0, , .		0

#	ARTICLE	IF	CITATIONS
360	A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 163, 76-82.	0.3	4
361	Cranial neuropathies in advanced nasopharyngeal carcinoma: Neurological recovery after modern radiotherapy and systemic chemotherapy. <i>Radiotherapy and Oncology</i> , 2021, 163, 221-228.	0.3	3
362	Split-field versus extended-field step-and-shoot IMRT techniques in nasopharyngeal cancer: a report of acute and late toxicities. <i>Journal of Radiotherapy in Practice</i> , 0, , 1-7.	0.2	0
363	Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 99-104.	0.6	3
364	Patient and Treatment Factors in Concurrent Chemoradiotherapy. , 2017, , 189-201.		3
365	High-Dose Static and Dynamic Intensity-Modulated Radiotherapy Combined with Chemotherapy for Patients with Locally Advanced Nasopharyngeal Carcinoma Improves Survival and Reduces Brainstem Toxicity. <i>Medical Science Monitor</i> , 2018, 24, 8849-8859.	0.5	8
366	Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis. <i>Medical Science Monitor</i> , 2020, 26, e922244.	0.5	6
367	Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy. <i>PLoS ONE</i> , 2015, 10, e0119101.	1.1	15
368	Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0130464.	1.1	13
369	Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. <i>PLoS ONE</i> , 2015, 10, e0136752.	1.1	19
370	Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy. <i>PLoS ONE</i> , 2016, 11, e0154501.	1.1	14
371	The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0194733.	1.1	37
372	Evaluation of Acute Toxicity and Early Clinical Outcome in Head and Neck Cancers Treated With Conventional Radiotherapy and Simultaneous Integrated Boost Arc Radiotherapy. <i>World Journal of Oncology</i> , 2017, 8, 117-121.	0.6	14
373	Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy. <i>Aging</i> , 2020, 12, 1857-1866.	1.4	8
374	Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 14068-14077.	0.8	18
375	Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 6763-6774.	0.8	18
376	Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 46211-46218.	0.8	10
377	Optimization of cervical lymph node clinical target volume delineation in nasopharyngeal carcinoma: a single center experience and recommendation. <i>Oncotarget</i> , 2018, 9, 26980-26989.	0.8	6

#	ARTICLE	IF	CITATIONS
378	Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. <i>Oncotarget</i> , 2015, 6, 38381-38397.	0.8	78
379	Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015, 6, 38296-38307.	0.8	10
380	Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy. <i>Oncotarget</i> , 2015, 6, 39373-39383.	0.8	19
381	Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 13060-13068.	0.8	80
382	A new staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results of a prospective multicentric clinical study. <i>Oncotarget</i> , 2016, 7, 15252-15261.	0.8	20
383	Parotid area lymph node metastases from preliminarily diagnosed patients with nasopharyngeal carcinoma: report on tumor characteristics and oncologic outcomes. <i>Oncotarget</i> , 2016, 7, 19654-19665.	0.8	6
384	The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 20680-20690.	0.8	15
385	Revalidation of a prognostic score model based on complete blood count for nasopharyngeal carcinoma through a prospective study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 467-477.	0.7	2
386	Whole brain radiotherapy using four-field box technique with tilting baseplate for parotid gland sparing. <i>Radiation Oncology Journal</i> , 2019, 37, 22-29.	0.7	7
387	Intensity-modulated radiation therapy in head-and-neck carcinomas. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 425-433.	0.3	5
388	Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study. <i>Cancer Research and Treatment</i> , 2018, 50, 861-871.	1.3	38
389	The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era. <i>Cancer Research and Treatment</i> , 2019, 51, 34-42.	1.3	15
390	Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1449-1463.	1.3	11
391	Pediatric advanced stage nasopharyngeal carcinoma - case report. <i>Acta Medica Academica</i> , 2015, 44, 186.	0.3	3
392	Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy. <i>Chinese Journal of Cancer</i> , 2013, 32, 494-501.	4.9	26
393	Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2013, 32, 525-532.	4.9	35
394	Prognostic Factors on Overall Survival of Newly Diagnosed Metastatic Nasopharyngeal Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3169-3173.	0.5	18
395	Advances and Challenges in Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1687-1692.	0.5	26

#	ARTICLE	IF	CITATIONS
396	Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco. <i>Cancer Control</i> , 2021, 28, 107327482110505.	0.7	5
397	A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 165, 14-19.	0.3	1
398	The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2021, 41, 1195-1227.	3.7	128
399	Nasopharyngeal carcinoma: Current treatment options and future directions. <i>Journal of Nasopharyngeal Carcinoma</i> , 2014, , .	0.0	0
400	Emerging prognostic factors in Nasopharyngeal carcinoma. <i>Journal of Nasopharyngeal Carcinoma</i> , 2014, , .	0.0	0
401	Genetic association on radiation induced mucosal and skin toxicity in patients with nasopharyngeal carcinoma. <i>Journal of Nasopharyngeal Carcinoma</i> , 2014, , .	0.0	0
402	New Radiotherapy Techniques for the Prevention of Radiotherapy-Induced Xerostomia. , 2015, , 147-164.		0
404	Management of Nasopharyngeal Carcinoma. , 2016, , 445-473.		0
405	Atypical Presentation of Nasopharyngeal Carcinoma. <i>Hematology &amp; Transfusion International Journal</i> , 2016, 2, .	0.1	0
406	Treatment of Viral-Associated HNC (OPC and NPC). , 2017, , 177-188.		0
408	Radiation Oncology Physician Practice in the Modern Era: A Statewide Analysis of Medicare Reimbursement. <i>Cureus</i> , 2017, 9, e1192.	0.2	3
409	Effects of intensity-modulated radiotherapy and chemoradiotherapy on attention in patients with nasopharyngeal cancer. <i>Oncotarget</i> , 2017, 8, 60390-60400.	0.8	2
410	Cytotoxic Chemotherapy and Targeted Therapy in Nasopharyngeal Cancer. , 2018, , 251-265.		0
411	Twice Operations for Parotid Metastasis of Nasopharyngeal Carcinoma Patient after Radical Intensity-Modulated Radiotherapy: A Case Report. <i>Journal of Cancer Research Updates</i> , 2018, 6, 78-80.	0.3	0
412	The maximum diameter of cervical lymph node was not a prognostic factor for local-regional advanced nasopharyngeal carcinoma treated with intensity modified radiotherapy. <i>Translational Cancer Research</i> , 2019, 8, 802-810.	0.4	1
413	éé,éf"ç™Œã®é«ç²³/4âº   æ"³/4âº „ç·šæ²»ç™,. <i>Journal of Otolaryngology of Japan</i> , 2019, 122, 1262-1264.	0.1	2
414	miRâ€¹182â€¹5p contributes to radioresistance in nasopharyngeal carcinoma by regulating BNIP3 expression. <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	6
415	Overview of head and neck cancer management. , 2020, , 1-32.		0

#	ARTICLE	IF	CITATIONS
416	Diagnostic Imaging of Nasopharyngeal Carcinoma. , 2020, , 13-42.		0
417	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up. Radiation Oncology, 2021, 16, 215.	1.2	7
418	A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study. American Journal of Cancer Research, 2017, 7, 346-356.	1.4	8
419	A low dose of AZD8055 enhances radiosensitivity of nasopharyngeal carcinoma cells by activating autophagy and apoptosis. American Journal of Cancer Research, 2019, 9, 1922-1937.	1.4	3
420	Imaging of Complications of Chemoradiation. Neuroimaging Clinics of North America, 2022, 32, 93-109.	0.5	1
421	Deep Learning-Augmented Head and Neck Organs at Risk Segmentation From CT Volumes. Frontiers in Physics, 2021, 9, .	1.0	6
422	Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options. Frontiers in Oncology, 2021, 11, 635737.	1.3	19
423	Risk of Stroke in Nasopharyngeal Cancer Survivors. Neurology, 2022, 98, .	1.5	2
424	Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. Clinical Genitourinary Cancer, 2022, 20, e94-e103.	0.9	1
425	The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. Head and Neck, 2022, 44, 518-529.	0.9	5
426	Local control and failure patterns after intensity modulated radiotherapy with reduced target volume delineation after induction chemotherapy for patients with T4 nasopharyngeal carcinoma. Translational Oncology, 2022, 16, 101324.	1.7	6
427	Construction of nomograms for nasopharyngeal carcinoma containing primary tumor size and SEER stage. Translational Cancer Research, 2020, 9, 6939-6954.	0.4	6
428	Radical resection for solitary thoracic spinous-process metastasis: a case report and technical note. Spinal Cord Series and Cases, 2022, 8, 8.	0.3	0
429	A Commentary on: Long-term outcomes of induction chemotherapy followed by intensity modulated radiotherapy and adjuvant chemotherapy in nasopharyngeal carcinoma patients with N3 disease. Translational Oncology, 2022, 15, 101278.	1.7	1
430	Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 101-113.	0.4	17
431	Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era. International Journal of Medical Sciences, 2022, 19, 267-273.	1.1	6
432	Landscape of mortality during and within thirty days after non-palliative radiotherapy across eleven major cancer types. Radiotherapy and Oncology, 2022, 167, 308-316.	0.3	2
433	Management of Nasopharyngeal Carcinoma in Elderly Patients. Frontiers in Oncology, 2022, 12, 810690.	1.3	5



#	ARTICLE	IF	CITATIONS
434	Semi-supervised NPC segmentation with uncertainty and attention guided consistency. Knowledge-Based Systems, 2022, 239, 108021.	4.0	41
435	Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncology, 2022, 126, 105736.	0.8	4
436	Radiotherapy for nasopharyngeal cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 168-173.	0.6	6
437	Institutionally validated nomogram predicting prognosis for older patients with nonmetastatic nasopharyngeal carcinoma. Future Oncology, 2022, , .	1.1	1
438	Modern Radiation Oncology: From IMRT to Particle Therapy – Present Status and the Days to Come. Indian Journal of Medical and Paediatric Oncology, 2022, 43, 047-051.	0.1	0
439	Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort. Cancers, 2022, 14, 1261.	1.7	9
440	High Superior-Middle Pharyngeal Constrictor Muscle Mean Dose Correlates with Severe Late Lung Infection and Survival in Nasopharyngeal Cancer Patients. Cancer Management and Research, 2022, Volume 14, 1063-1073.	0.9	4
441	Pathogenesis and Amelioration of Radiation-Induced Oral Mucositis. Current Treatment Options in Oncology, 2022, 23, 311-324.	1.3	12
442	De-escalating elective nodal irradiation for nasopharyngeal carcinoma. Lancet Oncology, The, 2022, 23, 441-443.	5.1	0
443	Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	1
444	Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents. Frontiers in Oncology, 2021, 11, 814881.	1.3	1
445	Proton Beam Therapy for Locally Advanced Head and Neck Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 81-87.	0.6	2
446	Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma. JAMA Network Open, 2021, 4, e2138444.	2.8	0
447	Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions. Cells, 2022, 11, 32.	1.8	6
448	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. Cancers, 2022, 14, 1923.	1.7	1
449	The Janus Face in Defining the Optimal Radiation Dose for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2022, 113, 114-116.	0.4	2
456	Is fractionated robotic stereotactic body radiosurgery optional salvage treatment for the re-irradiation of locally recurrent nasopharyngeal carcinoma?. Journal of Cancer Research and Therapeutics, 2022, 18, 66.	0.3	4
457	Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute. Journal of Cancer Research and Therapeutics, 2022, 18, 133.	0.3	1

#	ARTICLE	IF	CITATIONS
459	Survival among subgroups of patients with stage II nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2022, 12, 7007.	1.6	2
460	Effect of radiotherapy and chemotherapy on the survival rate of Asian Americans with nasopharyngeal carcinoma. <i>Precision Radiation Oncology</i> , 0, , .	0.4	0
461	Construction and validation of a biochemical signature to predict the prognosis and the benefit of induction chemotherapy in patients with nasopharyngeal carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1635-1647.	1.4	0
462	Review of functional magnetic resonance imaging in the assessment of nasopharyngeal carcinoma treatment response. <i>Precision Radiation Oncology</i> , 2022, 6, 177-185.	0.4	1
463	Reduction in severity of radiation-induced dermatitis in head and neck cancer patients treated with topical aloe vera gel: A randomized multicenter double-blind placebo-controlled trial. <i>European Journal of Oncology Nursing</i> , 2022, 59, 102164.	0.9	9
464	In-vivo skin dose measurement using gafchromic EBT3 film dosimetry in the radiation therapy of Head and Neck cancers: 2DRT versus IMRT. <i>Journal of Radiation Research and Applied Sciences</i> , 2022, 15, 170-174.	0.7	2
465	A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
467	Acute toxicity in patients treated with concurrent chemoradiotherapy with proton versus intensity-modulated radiation therapy for nonmetastatic head and neck cancers. <i>Head and Neck</i> , 2022, 44, 2386-2394.	0.9	2
468	Acute radiation dermatitis among patients with nasopharyngeal carcinoma treated with proton beam therapy: Prognostic factors and treatment outcomes. <i>International Wound Journal</i> , 0, , .	1.3	2
469	Organs-at-risk dose constraints in head and neck intensity-modulated radiation therapy using a dataset from a multi-institutional clinical trial (JCOG1015A1). <i>Radiation Oncology</i> , 2022, 17, .	1.2	10
470	Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
471	Development and validation of prognostic nomograms in patients with ascending type of nasopharyngeal carcinoma: A retrospective study based on <scp>SEER</scp> database. <i>Head and Neck</i> , 0, , .	0.9	3
472	Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-16.	0.7	1
473	Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2022, 134, 106139.	0.8	7
474	Radiation-induced hemorrhagic vasculopathy and seventh and eighth nerve complex neuropathy. <i>Annals of Indian Academy of Neurology</i> , 2022, 25, 921.	0.2	0
475	Healing Harmonies: The Therapeutic Power of Music. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
476	Adult Head and Neck Rhabdomyosarcoma: Management, Outcomes, and the Effect of Intensity Modulated Radiation Therapy on Locoregional Control. <i>Advances in Radiation Oncology</i> , 2022, 7, 101055.	0.6	2
478	Is a high-risk clinical target volume required? Evaluation of the dosimetric feasibility based on T staging. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
480	Real world presentation and treatment outcomes with a predominant induction chemotherapy based approach in nasopharyngeal carcinoma: a sixteen year report from a teaching hospital in India. Cancer Investigation, 0, , 1-23.	0.6	0
482	CACA guidelines for holistic integrative management of thyroid cancer. , 2022, 1, .		0
483	Post-irradiation sarcoma after definitive radiation therapy for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2023, 178, 109423.	0.3	0
484	Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical <sc>intensityâ€modulated</sc> radiotherapy with concurrent chemotherapy. Head and Neck, 2023, 45, 417-430.	0.9	2
485	Current Radiotherapy Considerations for Nasopharyngeal Carcinoma. Cancers, 2022, 14, 5773.	1.7	7
486	Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?. Radiotherapy and Oncology, 2023, 179, 109445.	0.3	7
487	Immunotherapy for Nasopharyngeal Cancer. , 2023, , 1-13.		0
488	Long-term outcomes of nasopharyngeal carcinoma treated with helical tomotherapy using simultaneous integrated boost technique: A 10-year result. Frontiers in Oncology, 0, 12, .	1.3	1
489	A rare pattern of local recurrence in the nasopharyngeal carcinoma: Case report. Otolaryngology Case Reports, 2023, 27, 100518.	0.0	0
490	Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation. Radiotherapy and Oncology, 2023, 183, 109595.	0.3	2
491	Recent advances in Nasopharyngeal cancer management: from diagnosis to theranostics. Current Pharmacogenomics and Personalized Medicine, 2023, 20, .	0.2	0
492	Correlation between Neutrophil to Lymphocyte Ratio and Oral Mucositis during Radiotherapy for Head and Neck Cancer. Advances in Clinical Medicine, 2023, 13, 1899-1905.	0.0	0
493	The prognostic nutritional index represents a novel inflammation-nutrition-based prognostic factor for nasopharyngeal carcinoma. Frontiers in Nutrition, 0, 10, .	1.6	4
494	Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensityâ€modulated radiotherapy treatment of <sc>T4</sc> nasopharyngeal carcinoma. Head and Neck, 2023, 45, 1130-1140.	0.9	1
495	Effect of radiotherapy interruption on nasopharyngeal cancer. Frontiers in Oncology, 0, 13, .	1.3	1
502	Principles of Radiation Oncology. , 2023, , 203-223.		0